文献速递肝胆胰外科围术期管理与 ERAS

加速康复外科在Ⅱ型巴德-吉亚利综合征腔房转流术中的临床疗效

[Clinical efficacy of enhanced recovery after surgery in atrial caval shunting for type Ⅱ Budd-Chiari syndrome].
PubMed 文献 · Zhonghua Wai Ke Za Zhi · 2017-01-01

该前瞻性随机单盲对照研究纳入82例Ⅱ型巴德-吉亚利综合征行腔房转流术患者,比较ERAS与传统围手术期管理。ERAS组术后胃管拔除、排气、进食及住院时间均缩短,应激和炎症指标变化趋势更优,并发症发生率更低(11.9% vs 30.0%)。

要点

  • ERAS可缩短Ⅱ型BCS腔房转流术后住院时间及管道留置时间。
  • ERAS减轻术后应激状态和炎症反应,并降低并发症发生率。
  • ERAS未增加手术时间、术中出血量或输血需求。

核心结论

  • Ⅱ型BCS腔房转流术围手术期应用ERAS有利于术后康复,减轻应激和炎症反应,缩短住院时间,降低并发症发生率。

研究设计与样本

  • 前瞻性随机单盲对照研究,2014年1月至2016年6月河南省人民医院肝胆外科收治的Ⅱ型BCS行腔房转流术患者82例,对照组40例,ERAS组42例。

主要发现

  • ERAS组术后胃管拔除、尿管拔除、胸管拔除、肛门排气、开始进食、术后输液及术后住院时间均短于对照组(P<0.05)。
  • ERAS组疼痛评分低于对照组(2.9±0.4 vs 1.9±0.6,P<0.05)。
  • 两组胰岛素抵抗指数、C反应蛋白、IL-6和TNF-α变化趋势差异有统计学意义(P<0.05)。
  • ERAS组术后并发症发生率11.9%(5/42)低于对照组30.0%(12/40)(χ2=4.08,P<0.05)。

关键数值与推荐

  • 术后胃管拔除时间:对照组(3.7±0.5)d vs ERAS组(0.0±0.0)d(t=35.03,P<0.05)。
  • 术后住院时间:对照组(11.4±1.0)d vs ERAS组(7.8±0.6)d(t=14.22,P<0.05)。
  • 术后并发症发生率:对照组30.0%(12/40) vs ERAS组11.9%(5/42)(χ2=4.08,P<0.05)。

临床怎么用

  • 对Ⅱ型BCS行腔房转流术的患者,可考虑采用ERAS围手术期管理方案以促进术后恢复。

局限性

  • 单中心研究,样本量82例,随访时间2~22个月(中位12个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical efficacy of enhanced recovery after surgery(ERAS) in atrial caval shunting (ACS) for type Ⅱ Budd-Chiari syndrome(BCS). Methods: The clinical data of patients underwent ACS for type Ⅱ BCS in the Henan Province People's Hospital from January 2014 to June 2016 were prospectively analyzed.Randomized and single-blind, controlled study was performed among the patients, and all of them underwent ACS and were divided into control group (patients underwent traditional perioperative management) and ERAS group (patients underwent ERAS perioperative management) based on a random number table.Operational and postoperative data, levels of inflammatory cytokines, stress state evaluation and postoperative complications were observed.The comparison between the two groups was evaluated with an independent sample t test.The trend analyses for variables were done using repeated measures ANOVA.The count data were analyzed using the chi-square test or Fisher exact. Results: Eighty-two patients were screened for eligibility, and allocated into the control group (40 patients) and the ERAS group (42 patients). All patients underwent ACS successfully with no death.Comparison of intraoperative status: operation time, volume of intraoperative blood and number of patients receiving blood transfusion were (211.0±12.9) minutes vs. (207.7±10.7) minutes, (167.5±28.3) ml vs. (165.0±28.4) ml and 3 cases vs. 1 case between the control group and the ERAS group, respectively, showing no difference between the two groups (t=0.90, 0.29, χ2=0.32, all P>0.05). Comparison of postoperative status: time of gastric tube removal, time of catheter removal, time of chest tube, time to flatus, time of food intake, duration of postoperative infusion, duration of postoperative hospital stay and numeric rating scale were (3.7±0.5)days vs. (0.0±0.0)days, (2.3±0.7)days vs. (1.4±0.5)days, (3.7±0.7)days vs. (2.3±0.5)days, (75.2±3.8)hours vs. (46.6±4.2)hours, (75.7±4.7)hours vs. (21.4±2.1)hours, (10.0±1.0)days vs. (5.8±0.9)days, (11.4±1.0)days vs. (7.8±0.6)days, 2.9±0.4 vs. 1.9±0.6 between the control group and the ERAS group, respectively, with statistically differences (t=35.03, 4.36, 8.10, 22.89, 47.78, 14.75, 14.22, 6.13, all P<0.05). Stress state evaluation: the levels of IR were (2.7±0.1) vs.(2.7±0.1), (8.8±0.7) vs. (5.2±0.3), (11.0±0.5) vs. (7.3±0.5), (4.9±0.2) vs. (3.9±0.1), and the levels of C-reaction protein were (14.6±1.3)mg/L vs.(14.6±1.1) mg/L, (101.2±13.6) mg/L vs. (89.5±6.9) mg/L, (62.7±8.6) mg/L vs. (56.4±8.4) mg/L, (46.4±6.7) mg/L vs. (40.0±5.6) mg/L from pre-operation to postoperative day 1, 3 and 5 between the control group and the ERAS group, respectively, with statistically significant differences in changing trends(F=136.61, 4.97, both P<0.05). Comparisons of levels of inflammatory cytokines: the levels of IL-6 were (43.1±2.7) ng/L vs. (43.6±3.6) ng/L, (135.1±6.4) ng/L vs. (117.4±5.7) ng/L, (145.4±6.7) ng/L vs. (128.5±5.5) ng/L, (93.3±3.7) ng/L vs. (88.0±3.9) ng/L, and the levels of TNF-α were (10.4±0.3)mmol/L vs. (10.4±0.3) mmol/L, (14.4±0.4) mmol/L vs. (12.6±0.4) mmol/L, (15.6±0.4) mmol/L vs. (13.8±0.4) mmol/L, (12.3±0.7) mmol/L vs. (11.4±0.6) mmol/L from pre-operation to postoperative day 1, 3 and 5 between the control group and the ERAS group, respectively, with statistically significant differences in changing trends (F=15.15, 21.45, both P<0.05). Comparison of postoperative complications: incidence of complications was 30.0%(12/40) in the control group and 11.9%(5/42) in the ERAS group, and the numbers of patients with nausea and vomiting, respiratory complications and cardiovascular complications were 4, 3, 5 cases in the control group and 3, 1, 1 case in the ERAS group, respectively, showing statistically differences in the incidence of complications(χ2=4.08, P<0.05). All the 82 patients were followed up for 2 to 22 months (median time, 12 months), no patients received reoperation or re-admitted to the hospital duo to complications. Conclusion: ERAS management in the perioperative period of ACS for BCS is beneficial to postoperative recovery of patients, and can relieve postoperative stress state and inflammatory response, reduce the duration of hospital stay, and incidence of postoperative complications. 目的: 探讨加速康复外科(ERAS)在Ⅱ型巴德-吉亚利综合征(BCS)腔房转流术中的应用价值。 方法: 选取2014年1月至2016年6月河南省人民医院肝胆外科收治的Ⅱ型BCS患者进行前瞻性研究。采用随机、单盲、对照方法,通过随机数字表法将符合纳入和排除标准的患者分为对照组和ERAS组。两组均行腔房转流术。对照组患者围手术期采用传统处理方案,ERAS组患者围手术期采用ERAS处理方案。观察两组患者的手术情况、术后情况、炎症指标、应激状态指标和术后并发症情况。采用电话和门诊复诊相结合的方式进行随访,随访截至2016年8月。组间数据的比较采用独立样本t检验;各指标趋势比较采用重复测量方差分析;计数资料比较采用χ2检验或Fisher确切概率法。 结果: 共有82例患者符合纳入和排除标准,其中对照组40例,ERAS组42例。两组患者均顺利完成手术,无死亡病例。对照组和ERAS组的手术时间、术中出血量分别为(211.0±12.9)min和(207.7±10.7)min、(167.5±28.3)ml和(165.0±28.4) ml,分别有3例和1例患者输血,差异均无统计学意义(t=0.90、0.29,χ2=0.32,P值均>0.05)。对照组和ERAS组术后胃管拔除时间、尿管拔除时间、胸管拔除时间、肛门排气时间、开始进食时间、术后输液时间、术后住院时间、疼痛评分分别为(3.7±0.5)d和(0.0±0.0)d、(2.3±0.7)d和(1.4±0.5)d、(3.7±0.7)d和(2.3±0.5)d、(75.2±3.8)h和(46.6±4.2)h、(75.7±4.7)h和 (21.4±2.1)h、(10.0±1.0)d和 (5.8±0.9)d、(11.4±1.0)d和(7.8±0.6)d、(2.9±0.4)分和(1.9±0.6)分,差异均有统计学意义(t=35.03、4.36、8.10、22.89、47.78、14.75、14.22、6.13,P值均<0.05)。对照组和ERAS组患者术前、术后1、3、5 d胰岛素抵抗指数分别为2.7±0.1和2.7±0.1、8.8±0.7和5.2±0.3、11.0±0.5和7.3±0.5、4.9±0.2和3.9±0.1;血清C反应蛋白分别为(14.6±1.3)mg/L和 (14.6±1.1) mg/L、(101.2±13.6) mg/L和(89.5±6.9) mg/L、(62.7±8.6) mg/L和 (56.4±8.4) mg/L、(46.4±6.7) mg/L和(40.0±5.6) mg/L;两组胰岛素抵抗指数和血清C反应蛋白水平变化趋势相比,差异均有统计学意义(F=136.61,4.97,P值均<0.05)。对照组和ERAS组患者术前、术后1、3、5 d白细胞介素-6(IL-6)分别为(43.1±2.7) ng/L和 (43.6±3.6) ng/L、(135.1±6.4) ng/L和 (117.4±5.7)ng/L、(145.4±6.7) ng/L和(128.5±5.5) ng/L、(93.3±3.7) ng/L和 (88.0±3.9) ng/L;血清肿瘤坏死因子-α(TNF-α)分别为(10.4±0.3)mmol/L和 (10.4±0.3) mmol/L、(14.4±0.4) mmol/L和 (12.6±0.4) mmol/L、(15.6±0.4) mmol/L和(13.8±0.4) mmol/L、(12.3±0.7) mmol/L和(11.4±0.6) mmol/L;两组患者术前、术后1、3、5 d血清IL-6和TNF-α水平变化趋势相比,差异均有统计学意义(F=15.15,21.45,P值均<0.05)。对照组和ERAS组患者术后并发症发生率分别为30.0%(12/40)和11.9%(5/42),其中恶心呕吐、呼吸系统并发症、心血管系统并发症分别有4例和3例、3例和1例、5例和1例,差异有统计学意义(χ2=4.08,P<0.05)。所有患者术后均获得随访,随访时间为2~22个月,无因术后并发症再入院患者。 结论: Ⅱ型BCS腔房转流术围手术期应用ERAS有利于患者术后康复,减轻患者应激状态和炎症反应,缩短住院时间,降低术后并发症发生率。.

来源:Zhonghua Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Tian GJ, Li DY, Yu HB, et al. [Clinical efficacy of enhanced recovery after surgery in atrial caval shunting for type Ⅱ Budd-Chiari syndrome]. Zhonghua Wai Ke Za Zhi. 2017. PMID: 28870052. doi:10.3760/cma.j.issn.0529-5815.2017.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。